Earlier this week, Nuclear Medicine Europe, the European Industry Association for Nuclear Medicine, held their yearly general assembly, at which Daniel Rossetto introduced ARTBIO as a new member. ARTBIO is proud to partner with Nuclear Medicine Europe to raise awareness and advance #nuclearmedicine in the region. We are committed to redefining cancer care as we develop a new class of #alpha #radioligand therapies as well as their ecosystem that maximizes their potential. #Pb212 #radioligandtherapy #RLT #biotech #ART
ARTBIO
Biotechnology Research
Cambridge, Massachusetts 5,590 followers
Empowering patient-centric advances in cancer care
About us
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
- Website
-
www.artbio.com
External link for ARTBIO
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
Cambridge, Massachusetts, US
-
Get directions
Oslo, NO
-
Get directions
Basel, CH
-
Get directions
London, GB
Employees at ARTBIO
Updates
-
ARTBIO Chief Scientific Officer Nick Pullen will be attending the 2nd Annual Boston Radionuclide Theranostics Forum tomorrow hosted by our partner Eckert & Ziegler SE at Morrison Foerster in Boston, MA. This forum will bring together leading experts in the field of #radiotheranostics and will build on the momentum of recent developments and approvals in the #radionuclide space. If you’re attending, connect with Nick to learn about how ARTBIO is offering a promising new approach to #cancer treatment with our #alpha #radioligand therapies. #RadionuclideTheranostics #Pb212 #radioligandtherapy #RLT #biotech
-
ARTBIO reposted this
We have a position open in the Early Discovery team at ARTBIO, Cambridge. This is a great opportunity to join the Radioligand Therapy field. Please feel free to reach out if you are interested.
-
Our development partnership with FogPharma, announced today, holds a lot of potential to advance cancer treatment innovation. By leveraging both ARTBIO’s #AlphaDirect™ platform and Fog’s best-in-class Helicon™ Therapeutics platform, we believe we have the opportunity to create a new class of #Helicon enabled #alpha #radioligand #therapeutics (HEARTS) that can optimize efficacy and safety, to transform patient outcomes. We are set up for a strong collaboration with complementary teams who will put their hearts into driving patient benefits. Read more here: https://lnkd.in/gh6CJqV8 #radiopharmaceuticals #nuclearmedicine #radioligandtherapy #RLT #biotech
We’re thrilled to announce a collaboration with the world-class team at ARTBIO that expands our pipeline of cancer therapies into #radiopharmaceuticals, a class of drugs we believe will make an extraordinary impact on patient outcomes. Along with ARTBIO we will be co-creating and co-commercializing Helicon-enabled alpha-particle radioligand therapies, drawing on the unique strengths of each of our platforms to produce a new category of targeted radioligand therapy. We believe the combination could produce the best radiopharmaceutical platform that exists in our industry today: On the one side, ARTBIO is uniquely able to accomplish distributed manufacturing of lead-212 (²¹²Pb), one of the most promising isotopes for radiopharmaceutical use but that is challenging to utilize because of its short half-life. On the other side, Fog’s Helicon platform could be a best-in-class carrier of radiopharmaceuticals because of our ability to precisely tune our peptides to control tissue distribution and half-life. The general hyper-tunability of Helicons opens new possibilities both for intracellular targeting — where Fog’s wholly-owned pipeline is focused — as well as for extracellular delivery. At the intersection of these two unmatched platforms, there’s huge potential to create therapies that improve, extend and save the lives of people with cancer. Learn more in our press release: https://bwnews.pr/3wBXF7L #radioligandtherapy #cancer #oncology #peptides #Helicons #radiopharmaceutical #patients
-
-
We are excited to announce the expansion of our #alpha #radioligand #therapy #manufacturing network through our #partnership with Nucleus RadioPharma, a leading CDMO with deep expertise in #radiopharmaceuticals. This collaboration will broaden our manufacturing and distribution capabilities throughout the Northern and Midwest regions of the US as we develop our alpha radioligand therapies based on the ideal isotope #Pb212. Read more here: http://bit.ly/3JNP1Ge #radiopharmaceuticals #nuclearmedicine #alpha #radioligandtherapy #RLT #biotech
Under the terms of the agreement, Nucleus will manufacture ARTBIO's 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001, using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology. "This strategic #partnership with ARTBIO underscores our unwavering commitment to transforming the lives of cancer patients through groundbreaking therapies," said CEO Charles Conroy, RPh, MBA. "We are thrilled to unite in our mission to address the pressing need for innovative radiopharmaceuticals, ensuring that patients have access to potentially life-changing treatments with highest quality and supply chain resilience." #Radiopharmaceuticals #Manufacturing #Radiotherapies https://hubs.ly/Q02wlJhM0
-
-
ARTBIO reposted this
Thank you! #ISMERAD 2024 - Alpha Therapy: New Approaches in Radionuclide Therapy was a great succes! The organising committee was proud to welcome almost 150 participants to the 9th edition of the #ISMERAD symposium. The official opening by Ignace Lemahieu pinpointing the advancements of nuclear medicine and theranostics in general, emphasising the role Belgian can/must play in this fast evolving world. Alpha Therapy as the red line through the day with interesting talks by Zena Wimana, Sven Van den Berghe, Matthijs Sevenois, Philippe Dasse, Filip Devos, Pascal Froment, Hans Van De Maele, Mike Sathekge, Michel Koole, Florian Rosar & Thomas Cocolios. Big thanks to our partners whom without we couldn’t have done this: PI Medical Diagnostic Equipment BV, Telix Pharmaceuticals Limited, ARTBIO, World Infinity Services srl/bv, BELNUC Association, Institut National des Radioéléments, SCK CEN, Eckert & Ziegler Isotope Products, TerThera b.v., PANTERA, ITM Isotope Technologies Munich SE, X-sanatec QC and EITA. Hope to see you all again - go for the 10th edition!
-
Last Friday, our Chief Technical Officer ✪ Philippe Dasse ✪ ☤ presented at the SCK CEN ISMERAD meeting sponsored by Institut Jules Bordet, where he talked about the ideal alpha emitter, Pb-212. Given its short-lived nature, #Pb212 has the potential to deliver its energy quickly, safely, and effectively to tumors, destroying them while lowering unwanted side effects. We look forward to developing our #radioligandtherapy based on this ideal isotope for the treatment of cancer. #radiopharmaceuticals #nuclearmedicine #alpha #radioligandtherapy #RLT #biotech
-
This week, Emanuele Ostuni and Vicki Jardine are heading to Lugano, Switzerland to attend the Advanced Prostate Cancer Consensus Conference. We look forward to learning about advances in the field, what is important from a patient’s perspective, and connecting with industry colleagues. #radiopharmaceuticals #nuclearmedicine #alpha #radioligandtherapy #RLT #biotech
-
-
We look forward to today's panel discussion on #radioligand #therapies with Roger Schibli, Jeevan Virk, Daniel Steiner, and Emanuele Ostuni, moderated by Ken Herrmann. Thank you Molecular Partners and Patrick Amstutz for the invitation and opportunity. https://bit.ly/4aQLyC6 #nuclearmedicine #radiopharmaceuticals #SwissBiotechDay
On Day 2 of #SwissBiotechDay 2024, MP will be sponsoring a panel discussion on Radioligand Therapies. Our SVP Research & Technology Daniel Steiner will join #radiopharma experts Emanuele Ostuni (ARTBIO), Roger Schibli (PSI Paul Scherrer Institut), Jeevan Virk (Novartis) in an exciting discussion moderated by Ken Herrmann (Universitätsmedizin Essen), covering our #RadioDARPin Therapy platform and how #Swiss companies and scientists are contributing to and leading this next era of innovation for cancer patients. Join us today at 2pm CET in Samarkand: https://bit.ly/4aQLyC6 #SwissBiotech #Biotechnology #DARPins
-
-
Our CEO Emanuele Ostuni shares an interesting MedCity News article that underscores the critical need to address logistics when delivering #radioligand therapies at scale. Learn more about how ARTBIO is well positioned to address these challenges: https://lnkd.in/en6FU-3s
This insightful article highlights the importance of well coordinated logistics for the delivery of #radiopharmaceuticals. ARTBIO is starting this journey by building a manufacturing network that is fit for the purpose of delivering therapeutics based on the powerful and short-lived Pb212 alpha precursor. The article also shines light on the growing demand for specialized staff to administer such therapies safely. A promising area for healthcare professionals looking to specialize. https://lnkd.in/eGKMfQNX